(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 15 January 2004 (15.01.2004)

PCT

(10) International Publication Number WO 2004/005333 A1

- (51) International Patent Classification7: A61K 31/13, G01N 33/68
- C07K 14/18,
- (21) International Application Number:

PCT/GB2003/002937

(22) International Filing Date:

7 July 2003 (07.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0215617.2

8 July 2002 (08.07.2002) GB

- (71) Applicant (for all designated States except US): UNIVER-SITY OF LEEDS [GB/GB]; Leeds LS2 9JT (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ROWLANDS, David [GB/GB]; School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT (GB). GRIFFIN, Stephen [GB/GB]; School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT (GB).

- (74) Agent: HARRISON, Goddard, Foote; Belgrave Hall, Belgrave Street, Leeds LS2 8DD (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF HEPATITIS C VIRUS (HCV) P7 PROTEIN

(57) Abstract: The present invention relates to the use of hepatitis C virus (HCV) p7 protein, and particularly but not exclusively, to its use in rationalised drug design and as a screen for antiviral therapeutic agents.